Often, cancerous cells produce aberrant DNA molecules which are difficult to detect by normal genome sequencing techniques. Fluorescent In-Situ Hybridization (FISH) is a highly sensitive and specific detection method for identifying these cytogenetic changes. Precision for Medicine (formerly ApoCell) develops state-of-the-art FISH assays to detect abnormalities in both hematological and solid organ tumors.
- FISH in CTCs, CECs, FFPE, frozen tissue, and bone
- Detect cellular genetic aberrations: multiploidy, translocations, amplifications or deletions
- Custom FISH probe design services
- Commercially available FISH assays
- Proprietary disease-specific FISH panels
The markers below are commonly utilized FISH targets; please visit our Test Menu for a more thorough listing.
In addition to examining changes in DNA by FISH, Precision for Medicine is also able to query modifications to RNA targets using ACD’s RNAscope ISH assays and technology. Commercially available or custom RNA ISH targets are available for incorporation into one of our integrated workflows.